Knight Therapeutics Inc. KHTRF
8.46 USD +0.05 (+0.59%)
At closeNov 12, 2026, 4:00 PM EST
8.41 Day range 8.41
4.11 52-week range 8.61
- YTD
- +94.48%
- 1 year
- +93.59%
News
marketbeat.com What Knight Therapeutics (GUD) Said on Its Q3 Earnings Call Knight Therapeutics TSE: GUD raised its 2026 revenue and adjusted EBITDA outlook after reporting third-quarter growth driven by its promoted products and launches in Canada and Latin America.
seekingalpha.com Knight Therapeutics Inc. (GUD:CA) Q3 2026 Earnings Call Transcript Knight Therapeutics Inc. (GUD:CA) Q3 2026 Earnings Call Transcript
marketbeat.com Knight Therapeutics Q2 Earnings Call Highlights Knight Therapeutics TSE: GUD reported record results for the first six months of 2026 and raised its full-year outlook, citing growth in its promoted products, contributions from recent launches and…
globenewswire.com Knight Therapeutics Announces Repayment of Revolving Credit Facility MONTREAL, June 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has repaid all amounts outstanding…
globenewswire.com Knight Therapeutics Announces Launch of TAVALISSE® in Mexico MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib…
globenewswire.com Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil MONTREAL, May 08, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) pharmaceutical company, announced today that its Brazilian affiliate, United Medical…
seekingalpha.com Knight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call Transcript Knight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call Transcript
globenewswire.com Knight Therapeutics Reports First Quarter 2026 Results Increased 2026 revenue guidance from $510 million to $525 million Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception
globenewswire.com Knight Therapeutics Inc. announces voting results from the Annual General Meeting MONTREAL, May 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) pharmaceutical company, announced today the voting results from…
seekingalpha.com Knight Therapeutics Inc. (GUD:CA) Shareholder/Analyst Call Prepared Remarks Transcript Knight Therapeutics Inc. (GUD:CA) Shareholder/Analyst Call Prepared Remarks Transcript
globenewswire.com Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) pharmaceutical company, will release its first quarter 2026 financial results on…
seekingalpha.com Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript
globenewswire.com Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results Delivered record-high revenues, Adjusted EBITDA 1 , Adjusted EBITDA per shar e 1 since inception Generated record high cash flow from operations since inception Provides 2026 revenues guidance of…
globenewswire.com Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call MONTREAL, March 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end…
defenseworld.net Knight Therapeutics (KHTRF) Expected to Announce Earnings on Thursday Knight Therapeutics (OTCMKTS:KHTRF - Get Free Report) is anticipated to release its resultson Thursday, March 19th. Analysts expect Knight Therapeutics to post earnings of ($0.0029) per share and…
globenewswire.com Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil MONTREAL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,…
globenewswire.com Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved…
seekingalpha.com Knight Therapeutics Inc. (GUD:CA) Q3 2025 Earnings Call Transcript Knight Therapeutics Inc. ( GUD:CA ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Samira Sakhia - President, CEO & Director Arvind Utchanah - Chief Financial Officer Amal…
globenewswire.com Knight Therapeutics Reports Third Quarter 2025 Results Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception Increased 2025 financial guidance
globenewswire.com Knight Announces Closing of US$100 Million Revolving Credit Facility MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has…
benzinga.com Stocks That Hit 52-Week Lows On Wednesday